Although sodium fluoride is a potent stimulator of bone formation, a c
lear role for this therapy in osteoporosis remains elusive. Controlled
clinical trials uniformly document an increase in bone mineral densit
y but have provided conflicting results concerning antifracture effica
cy. The increase in bone density is dose-dependent but higher doses ap
pear to affect biomechanical properties of the skeleton adversely. New
er preparations of slow-release sodium fluoride and monosodium fluorop
hosphate may clarify the role of fluoride in osteoporosis.